Core Insights - The company expects revenue for full year 2026 to be approximately $870 million to $880 million, reflecting a year-over-year growth of about 17% to 18% [1] - The anticipated adjusted EBITDA margin for 2026 is projected to be around 11.5% to 12.5% [1] - The year 2025 has been described as transformative for the company, achieving over 25% year-over-year revenue growth and free cash flow positivity for the first time [1] Company Performance - The company has executed strong commercial volumes and aims to drive best-in-class quality systems [1] - The comprehensive clinical evidence program, including AVALON and CAMELOT publications, supports the clinical superiority of Zio LTCM and market expansion [1] - The company is well-positioned for growth with multiple catalysts, including deeper penetration in primary care and population health through AI partnerships [1] Market Expansion - The company plans to expand into adjacent markets such as obstructive sleep apnea and continue its international execution [1] - There is a focus on mobile cardiac telemetry and leveraging AI-powered risk stratification partnerships to enhance market presence [1] - The company expresses confidence in delivering sustainable, profitable growth while transforming cardiac care for millions of patients globally [1]